Herzich Paul 4

What Happened

• Paul Herzich, Chief Technology Officer of Solid Biosciences (SLDB), recorded the vesting/conversion of performance and restricted equity and a small open‑market sale. Following conversion/vesting events on Jan 29 and Jan 31, 2026, Herzich sold 26,250 shares on Feb 2, 2026 for a weighted average price of $6.44, totaling approximately $168,969. The sale was a sell‑to‑cover to satisfy tax withholding obligations after PSU vesting (not a discretionary trade).

Key Details

• Transaction dates and amounts:
  • Jan 29, 2026: Conversion/exercise related entries for 54,925 shares (derivative conversion/related grant activity recorded).
  • Jan 29, 2026: Grants recorded totaling 170,000 shares and 85,000 shares (zero exercise price; derivative awards).
  • Jan 31, 2026: Conversion/exercise of 24,675 shares.
  • Feb 2, 2026: Open‑market sale of 26,250 shares at a weighted average $6.44, gross proceeds ≈ $168,969.
• Price details: weighted average $6.44; sale prices ranged from $6.295 to $6.580 (filing provides range and offers to supply per‑trade detail on request).
• Shares owned after transaction: not specified in the excerpt provided (see full Form 4 for “Ownership Following Reported Transaction”).
• Notable footnotes:
  • The sale was a sell‑to‑cover to cover withholding taxes after PSUs vested and was effected under a durable automatic sell instruction (adopted Aug 16, 2024) — not a discretionary sale by the reporting person.
  • PSUs convert one‑for‑one to common stock; one PSU performance milestone (25% of target) was certified on Jan 29, 2026, causing partial vesting.
  • Grants and vesting schedules: PSU/RSU grants and an option were noted with multi‑year vesting schedules (see footnotes for four‑year vesting detail).
• Filing timeliness: Form was filed Feb 2, 2026 for transactions dated Jan 29–Feb 2, 2026; this filing appears timely under the two business‑day Form 4 requirement.

Context

• These entries reflect equity award vesting/conversion events (PSUs/RSUs/options) and a routine sell‑to‑cover to satisfy tax withholding—not an independent open‑market bet by the insider. For full ownership figures and the detailed breakdown of conversions vs. cancellations, consult the full Form 4 (Accession No. 0001193125-26-034076).